Johnson & Johnson (JNJ) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.

Johnson & Johnson (NYSE:JNJ) recently announced promising Phase 1 study results for Pasritamig, a novel antibody for advanced ...

Ethicon 4000 features proprietary 3D staple technology, a redesigned end effector and streamlined reload options. The company said it offers consistency from the first staple to the last to reduce ...

Johnson & Johnson shared positive ASCO 2025 results, including improved survival and remission in prostate and multiple ...

Johnson & Johnson shows strong profitability and solid value, but faces growth uncertainty, legal risks, and pricing ...

JNJ's 62-year streak of dividend growth, 3.4% yield, and disciplined capital allocation make it highly attractive for long-term, income-focused investors. The company is undervalued, trading at less ...

New Brunswick, New Jersey-based Johnson & Johnson (JNJ) primarily focuses on drug discovery and manufacturing but has a ...

Johnson & Johnson MedTech has launched its Kincise 2 surgical automated power tool system for knee and hip procedures, and ...

Leerink Partners downgraded their outlook for Johnson & Johnson (NYSE:JNJ) from Outperform to Market Perform. Analyst Price Forecast Suggests 17.34% Upside As of May 7, 2025, the average one-year ...

Johnson & Johnson (JNJ) announced Tuesday initial Phase 1 results of JNJ-79635322 (JNJ-5322), a novel investigational ...